MMP9 and breast carcinoma: It has been proposed that MMP9, a 92 kDa type IV collagenase, exerts its ability as a key mediator of extracellular matrix (ECM) remodeling and metastasis through degradation of type IV and V collagens, and acts as prognostic biomarker for breast cancer patients [20].